Sugi Predict

Sugi Predict / Compounds / SCHEMBL982343

SCHEMBL982343

SCHEMBL982343

CC1=C[C@@H](O)CC(C)(C)/C1=C/C=C(C)/C=C/C=C(C)/C=C/C=C/C(C)=C/C=C/C(C)=C/C=C1\C(C)=C[C@@H](O)CC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.41
▸ LMNA P02545 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ GMNN O75496 2/20 0.39
▸ PMP22 Q01453 2/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ ALDH1A1 P00352 8/20 0.36
▸ PTGS1 P23219 4/20 0.36
▸ DRD3 P35462 2/20 0.36
▸ SLCO1B3 Q9NPD5 1/20 0.36
▸ SLCO1B1 Q9Y6L6 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALOX15 P16050 3/20 0.35
▸ CYP3A4 P08684 3/20 0.33
▸ APP P05067 2/20 0.33
▸ SNCA P37840 2/20 0.33
▸ TRPV1 Q8NER1 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18582776 1.00 MAPT (0.41) MAPTLMNATSHRHIF1AGMNN
SCHEMBL2841262 1.00 MAPT (0.41) MAPTLMNATSHRHIF1AGMNN
SCHEMBL1463072 1.00 MAPT (0.41) MAPTLMNATSHRHIF1AGMNN
SCHEMBL18582741 0.94 MAPT (0.40) MAPTLMNATSHRHIF1AGMNN
SCHEMBL983577 0.94 MAPT (0.40) MAPTLMNATSHRHIF1AGMNN
SCHEMBL2842094 0.92 MAPT (0.42) MAPTLMNATSHRHIF1AGMNN
SCHEMBL18582730 0.88 MAPT (0.39) MAPTLMNATSHRHIF1AGMNN
SCHEMBL983165 0.88 MAPT (0.39) MAPTLMNATSHRHIF1AGMNN
SCHEMBL983166 0.88 MAPT (0.39) MAPTLMNATSHRHIF1AGMNN
SCHEMBL15286195 0.84 MAPT (0.36) MAPTLMNATSHRHIF1AGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019016384-A1 NOVEL ENZYME DSM IP ASSETS B.V. (NL) 2019-01-24 — — WO claimed
WO-2019016382-A1 NOVEL FERREDOXIN REDUCTASE DSM IP ASSETS B.V. (NL) 2019-01-24 — — WO claimed
WO-2019016383-A1 NOVEL FERREDOXIN DSM IP ASSETS B.V. (NL) 2019-01-24 — — WO claimed
WO-2013144595-A1 PERIDININ-CHLOROPHYLL BINDING PROTEINS PROTEIN TECHNOLOGIES LIMITED (GB) 2013-10-03 — — WO claimed
JP-8198789-A — — None — — JP disclosed
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE Axitan Ltd. (GB) 2026-05-28 — — US disclosed
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient LONZA SALES AG (CH) 2026-05-07 — — US disclosed
EP-4054348-B1 PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT LONZA SALES AG (CH) 2026-01-28 — — EP disclosed
US-12471609-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-11-18 — — US disclosed
US-12465075-B2 Particles containing a lipid matrix core and active ingredient LONZA SALES AG (CH) 2025-11-11 — — US disclosed
EP-4642253-A1 USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION Weforesea Ltd. (IL) 2025-11-05 — — EP disclosed
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE NUTRIQUEST, LLC 2025-09-11 — — US disclosed
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-03 — — US disclosed
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CARDAX PHARMA, INC. 2005-02-17 — — US disclosed
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-02-03 — — US disclosed
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression CARDAX PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-01-06 — — US disclosed
JP-H08198789-A EXTRACT CONTAINING CAROTENOID HAVING ANTIOXIDANT ACTIVITY, ITS PRODUCTION AND ANTIOXIDANT AND COLORANT RES INST FOR PROD DEV 1996-08-06 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CPT1A, TXNRD2, PC MAPT 4758/4885LMNA 1111/4885TSHR 3827/4885
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE ELOVL6, CROCC, ELOC MAPT 3063/4885LMNA 2049/4885TSHR 3909/4885
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE PIGS, GLO1, IGFBP6 MAPT 3007/4885LMNA 1769/4885TSHR 2564/4885
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 MAPT 4813/4885LMNA 29/4885TSHR 4469/4885
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 MAPT 4766/4885LMNA 34/4885TSHR 4220/4885
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A MAPT 3961/4885LMNA 716/4885TSHR 2664/4885
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient AUP1, MGLL, MBOAT4 MAPT 440/4885LMNA 1876/4885TSHR 3099/4885
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels PROC, TTPA, CYC1 MAPT 4035/4885LMNA 2351/4885TSHR 2794/4885
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease NFE2L2, GPX4, CYP11B2 MAPT 4360/4885LMNA 685/4885TSHR 3520/4885
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A MAPT 3908/4885LMNA 870/4885TSHR 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.